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ABSTRACT 
Background: Chronic liver diseases are among the main causes of death in adults 
in many countries and are usually diagnosed at late stages. Early detection may 
allow preventing disease progression. 
Objectives: To assess the feasibility of screening for unrecognized chronic liver 
diseases in a primary care nurse consultancy and report findings from screening. 
Methods: Subjects aged from 18 to 70 years were identified randomly from the 
health registry and invited to participate in a feasibility pilot study. Exclusion 
criteria were past or current history of liver diseases and lack of written informed 
consent. The nurse intervention consisted of collection of demographic and 
clinical data and performing a transient elastography of the liver. Transient 
elastography estimates the amount of fibrotic tissue in the liver by measuring liver 
stiffness. The procedure can be performed by nurses after a short training period. 
Results: Among 495 subjects without previously known liver disease included, 28 
(5.7%) had increased liver stiffness (≥6.8 KPa), indicating the presence of a 
chronic liver disease with fibrosis. Patients with increased liver stiffness were 
older and more frequently male and had higher frequency of metabolic syndrome, 
as compared to patients with normal liver stiffness. Non-alcoholic fatty liver was 
the most common cause of chronic liver disease. 
Discussion: A nurse-led intervention program is able to detect unrecognized 
chronic liver diseases in apparently healthy subjects. Early detection of chronic 
liver diseases is feasible in primary care and may facilitate interventions to prevent 
liver disease progression. 
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Introduction 
     Chronic liver diseases (CLD) represent a major health problem worldwide (The 
Lancet Editorial. 2013; Bell et al. 2008). The incidence of CLD is increasing in 
many areas of the world, including USA and Europe where they are among the top 
12 leading causes of death (Peery et al. 2012; Blanchier, Leleu, Peck-
Radosavljevic, Valla & Roudot-Thoraval. 2013). CLD encompass a number of 
conditions that are characterized by slow but persistent hepatic inflammation 
causing fibrosis (scar tissue) in the liver (Schuppan & Afdahl, 2008). Etiologic 
factors of CLD include chronic alcohol abuse, hepatitis C or B virus infections, 
and non-alcoholic fatty liver disease (NAFLD), a disease characterized by 
accumulation of fat in the liver associated with metabolic syndrome. Quite often, 
the chronic inflammation of the liver leads to cirrhosis. Once cirrhosis has 
developed, patients eventually die or require liver transplantation because of 
complications or liver cancer.   
     The unrelenting formation of fibrosis is fundamental to the process from liver 
inflammation to development of cirrhosis. The evolutionary process has three 
characteristics: transition to cirrhosis usually takes a very long period of time (as 
long as 20-30 years), does not cause symptoms, and severe fibrosis or cirrhosis 
cannot be identified reliably with standard laboratory tests (Schuppan & Afdahl, 
2008). Thus, CLD remain unrecognized for many years until patients develop 
complications or cancer. Fibrosis is reversible in early stages if the etiologic factor 
is identified and removed (Friedman, 2007; Dixon, Bhathal , Hughes & O’Brien, 
2004). Suppression of the causative factor leads to improved outcomes in all 
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etiologies of CLD (Schuppan & Afdahl, 2008) However, fibrosis is hardly ever 
reversible when cirrhosis has developed. Therefore, early identification of fibrosis 
is crucial to improve the outcome of patients with CLD.  Considering the absence 
of symptoms of CLD in initial stages, early identification would require mass 
screening of general population. 
     Until very recently, the only method effective for early identification of fibrosis 
was liver biopsy, a method that is invasive and may induce complications (Bravo, 
Sheth & Chopra, 2001). Few non-invasive methods for early detection of fibrosis 
have been reported that may be potentially useful tools for mass screening of CLD 
in the general population (Nguyen & Talwalkar, 2011; Martinez, Crespo, Navasa 
& Forns, 2011, Del Poggio & Colombo, 2009). One of these methods, transient 
elastography (TE), consists of the evaluation of the amount of scar tissue in the 
liver by measuring the velocity of propagation of a wave within the liver. TE has 
high sensitivity and specificity for detection of presence and degree of fibrosis 
with accuracy similar to that of liver biopsy (Castera, Forns & Alberti, 2008; 
Friedrich-Rust et al. 2008). The area under the receiver operating curve for 
significant fibrosis differs slightly among studies, the average being 91%. 
Currently, TE is performed in liver clinics of academic hospitals, either by trained 
physicians or nurses, for assessment of fibrosis in patients with known CLD. 
Moreover, a recent study suggests that TE may be useful for screening of CLD 
(Roulot et al. 2011). However, because of paucity of studies so far there is no 
recommendation yet on the possible use of TE as method of mass screening of 
CLD (Castera 2011). TE is a simple and painless procedure that is performed in a 
very short period of time. However, measurements can be difficult or even 
impossible in obese patients or those with a narrow intercostal space.  
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     Given the lack of symptoms of CLD, a reasonable approach to identify patients 
in early stages of fibrosis would be to use TE in primary care. In this regard, 
trained nurses could perform this technique as screening method of liver diseases 
as part of overall subjects’ health assessment. Training is key to the success of the 
procedure. The manufacturer offers half-day training course to learn the basic 
principles of the procedure and interpret the findings. However, this should be 
complemented with a number of supervised procedures with an operator with 
extensive experience in TE (Kettaneh, et al. 2007). In patients with confirmed 
CLD, nurses may then undertake educational interventions with the aim of halting 
liver disease progression and improving patients’ outcome (for example, 
counseling about stopping alcohol consumption in alcohol abusers or weight 
reduction and life style changes in patients with obesity and metabolic syndrome). 
On this background, we decided to perform a pilot feasibility study of a primary 
care nurse consultancy using TE to detect CLD in the general population.  
Methods 
Study design and Participants 
     This is a pilot feasibility study conducted in a public health district of 
Catalonia, in the city of Mataró, a town with 120,000 inhabitants. Subjects aged 
18 to 70 years were identified randomly from the state health registry using 
specific software and invited to participate in the study by a phone call. Exclusions 
were past or current history of liver disease and lack of informed consent. Five-
hundred and two subjects accepted to participate in the study. 
     Participants were seen in a nurse consultancy specifically set up for the study. 
Subjects received detailed information before signing the informed consent. The 
nurse then followed 3 steps. The first step consisted of collecting patients’ 
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demographics and history. Weight and height were recorded and arterial pressure 
measured using an automated sphygmomanometer. The second step consisted of 
collecting a blood sample for measurement of transaminasses (AST/ALT), glucose 
and serum lipids, and serological markers of hepatitis B and C infection. These 
two steps took 20 min in average per subject. Finally, the third step consisted of 
performing TE, which took 10 min in average.  
Transient elastography 
     TE was performed using a commercially available system (Fibroscan
R
, 
Echosens, Paris, France). The method of TE is discussed in detail elsewhere 
(Castera et al. 2008). Briefly, the system transmits a vibration of mild amplitude 
and low frequency trough the liver that induces an elastic shear that propagates 
within the liver. The speed of the shear wave is measured using pulse-echo 
ultrasound. The velocity of propagation of the wave correlates directly with the 
stiffness of the tissue, the harder the tissue, the faster the velocity of the wave. The 
stiffness is measured in kilopascals (kPa). The examination is performed with the 
patient lying flat on his/her back, with the right arm above the head. The tip of the 
probe transducer is placed on the skin between the ribs at the level of the right 
lobe of the liver. An ultrasound image allows locating a portion of the liver of 
approximately 4 cm long and stiffness is measured. The software indicates 
whether measurement has been successful or not. The final value reported is the 
median value of 10 successful measurements. The optimal cut-off value for the 
diagnosis of significant fibrosis has been suggested to be around 7 kPa, yet 
optimal cut-offs may vary according to etiological factors (Friedrich-Rust et al. 
2008). In the current study, the cut-off value chosen was 6.8 kPa. This cut-off 
level was selected because it has a high sensitivity and specificity in the detection 
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of significant liver fibrosis in patients with NAFLD, which was anticipated to be 
the most prevalent cause of liver disease in our population (Yoneda et al. 2008).  
     In the current study, two nurses were trained initially with the manufacturer’s 
course followed by about 250 examinations performed under the supervision of an 
expert nurse with 5 years of experience in TE working in a liver clinic of a 
university hospital (CB). Nurses were taught about the technique of performing 
TE, how to improve the success rate of measurements and interpret the results. 
Subjects with TE values above the cut-off were referred to a liver clinic for further 
evaluation of their disease. A member of the research group communicated with a 
hepatologist and received the feed-back after the consultation was made. 
Data collection 
     All data were collected in specifically designed case-report forms that were 
then transferred to a computerized data-base.  
Ethical considerations 
     The study was approved by the Institutional Review Board and fulfilled the 
current regulations about data confidentiality.  
Statistical analysis 
     Comparison of frequencies was performed with the chi-square test, while 
comparison of means was done with the unpaired t test. Data are reported as 
mean±standard deviation and percentages. The analysis was performed using the 
Stata 12.1 for Windows (Stata Corp, College Station, TX,  USA).  
Results 
     The baseline characteristics of the population studied are shown in table 1.  
Out of 502 patients evaluated, an accurate measurement of liver stiffness was 
achieved in 495 subjects (98.6%). In only 7 patients (1.4%) liver stiffness could 
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not be estimated because of an increased amount of adipose tissue in the 
abdominal wall. Results are referred to the 495 subjects with measurement of liver 
stiffness available. Questions arising about TE methodology were solved by a 
nurse expert in TE (CB) who was available for consultation during the study. 
     Twenty-eight of the 495 subjects (5.7%) had increased liver stiffness (≥6.8 
kPa) consistent with significant liver fibrosis, while the remaining subjects had 
normal liver stiffness. The presence of liver disease with fibrosis in subjects with 
increased liver stiffness was confirmed by a hepatologist using standard diagnostic 
procedures including ultrasonography and liver biopsy, in selected cases. Ninety 
percent of subjects with fibrosis had NAFLD, while the remaining 10% had 
alcoholic liver disease. Surprisingly, no cases of hepatitis C or B infection were 
found. Communications between the research team and the liver clinic were fluent 
and timely throughout the study. 
     A comparison of baseline characteristics of subjects categorized according to 
the cut-off level of liver stiffness is shown in table 2. Subjects with increased liver 
stiffness were more frequently male and older compared to subjects with normal 
liver stiffness. Moreover, subjects with increased liver stiffness had findings 
consistent with greater frequency of metabolic syndrome, including higher glucose 
and triglycerides concentration, higher BMI and arterial pressure, and increased 
waist circumference. As expected, mean AST and ALT levels were higher in 
subjects with increased liver stiffness.  
Discussion 
     The results of the current study demonstrate that a simple nurse-led 
intervention program that uses TE of the liver is able to detect CLD with 
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significant fibrosis in 5.7% of subjects from a cohort randomly selected from the 
general population without previously apparent liver disease.  
     A recent study reported the efficacy of a nurse-led intervention using TE in the 
assessment of fibrosis in patients with known or suspected liver disease evaluated 
in an academic hospital (McCorry et al. 2011). However, to our knowledge, this is 
the first nurse-led intervention program so far reported for screening of CLD in 
the general population. There are several aspects of this intervention that deserve a 
comment. First, the intervention was effective, as it was able to identify almost 6% 
of subjects with previously unknown CLD. The presence of liver disease was later 
confirmed by standard diagnostic procedures. The possibility of false negative 
results (patients with CLD with fibrosis that were not recognized with TE) cannot 
be ruled out completely. Nonetheless, it should be pointed out that TE is very 
sensitive in the detection of liver fibrosis (Martínez et al. 2011; Castera et al. 
2008; Friedrich-Rust et al. 2008). Second, given the lack of effective screening 
methods of liver fibrosis at present, this nurse-led intervention program of liver 
disease screening could be easily implemented in primary care because of its 
simplicity and safety. Third, nurses running this program should be trained on the 
use of TE to guarantee the accuracy of the technique. If the current results are 
confirmed in other studies and TE is proven to be cost-effective, this nurse-led 
program should be implemented in primary care as method of mass screening for 
identification of asymptomatic subjects with unrecognized liver diseases. The 
target population could consist of subjects attended for preventive measures, such 
as arterial pressure or lab check-ups or weight control, or even patients walking in 
for minor health problems (Fabrellas et al, 2011). No information exists with 
respect to the frequency of screening, but it can be suggested that subjects without 
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risk factors for liver diseases be screened at least once in their life, around the 
fourth or fifth decade, while subjects with risk factors be screened at regular 
intervals that remain to be defined. 
     It is important to emphasize that the current study was exclusively aimed at 
testing the hypothesis that a nurse-led program that uses TE is feasible to detect 
unrecognized CLD in the general population. The study was neither designed to 
evaluate the effects of nurse educational interventions in improving outcomes nor 
to assess the cost-effectiveness of this approach. Future studies should be 
performed to evaluate these issues. This type of program requires a formal 
agreement with a liver clinic for referring patients with abnormal results of TE for 
further evaluation. A last point that deserves a comment is that the majority of 
patients with unveiled chronic liver diseases had NAFLD (Ratziu, Bellentani, 
Cortez-Pinto, Day & Marchesini, 2010; Bellentani et al. 2000; Dam-Larsen et al. 
2004). The early diagnosis of this condition may allow nurse educational 
interventions to improve the metabolic syndrome and reduce its negative effects in 
the liver. A potential limitation of TE is the possibility of unsuccessful 
measurements in markedly obese patients. 
     In summary, a nurse-led intervention program based on TE is reported. This 
program was able to identify hidden CLD in 5.7% of subjects with unrecognized 
CLD from the general population. This type of nurse intervention is feasible and 
may have a role in screening and identification of CLD in the general population.  
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 Table 1: Characteristics of the subjects studied (n=495)* 
  M (SD) Normal values 
Age, years 47.2 ± 13.3    
Male gender  205 (41%)   
Caucasian  441 (89%)   
Current tobacco consumption  125 (25%)   
Excessive alcohol consumption **   46 (9%)  
Body mass index (Kg/m²) 27.6 ± 5.1  < 30  
Waist circumference    
     Male (cm) 96.3 ± 12.5  < 102  
     Female (cm) 88.4 ± 12.7  < 88  
Systolic blood pressure (mmHg) 124 ± 17   < 130  
Diastolic blood pressure  (mmHg) 78 ± 10  < 85  
Glucose (mg/dL) 92 ± 20  60-110  
HDL cholesterol    
     Male (mg/dL) 48 ± 10  < 35  
     Female (mg/dL) 57 ± 12  < 45  
Triglycerides (mg/dL) 114 ± 81  < 150  
AST (U/L) 23 ± 8  < 31 
ALT (U/L) 23 ± 13  < 34  
Liver stiffness (kPa) 4.7 ± 1.8  < 6.8  
 
* Values are mean±standard deviation or numbers and percentages (in brackets).  
** Greater than 21 and 14 drinking units per week in men and women, respectively. 
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
 
 
 
 
 
 
 
 
 
Table
 Table 2: Comparison of subjects without and with increased liver stiffness* 
  
Normal liver 
stiffness  
(n= 467) 
Increased liver 
stiffness  
(n= 28) p 
Age, years 46.7 ± 13.2 56.3 ± 10.8          <0.001 
Male gender  188 (40%) 17 (61%) 0.033 
Caucasian  415 (89%) 26 (93%) 0.576 
Current tobacco consumption 124 (27%) 1 (4%) 0.002 
Excessive alcohol consumption**  42 (9%) 4 (14%) 0.273 
Body Mass Index (Kg/m²) 27.2 ± 4.8 33.9 ± 5.8 <0.001 
Waist circumference    
     Male (cm) 95.2 ± 12.0  109 ± 12.1   <0.001 
     Female (cm)  87.8 ± 12.1  102 ± 8.5   <0.001 
Systolic Blood Pressure  (mmHg) 124 ± 17 132 ± 15 0.018 
Diastolic Blood Pressure (mmHg) 78 ± 10 79 ± 9 0.030 
Glucose (mg/dL) 91 ± 19 104 ± 26 0.001 
HDL cholesterol    
     Male (mg/dL) 47 ± 10 50 ± 13 0.399 
     Female (mg/dL) 57 ± 12 55 ± 10 0.500 
Triglycerides  (mg/dL) 109 ± 67 183 ± 179 <0.001 
AST  (U/L) 22 ± 7 31 ± 22 <0.001  
ALT  (U/L) 22 ± 12 32 ± 24  <0.001 
Liver stiffness (kPa) 4.4 ± 0.9 9.2 ± 4.3  <0.001 
 
* Values are mean±standard deviation or numbers and percentages. Numbers in brackets are 
percentages.  
** Greater than 21 and 14 drinking units per week in men and women, respectively.  
AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
 
